Multi-Specialty - CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Medical Cardiology, Interventional Cardiology, Lipid Medicine, Atherosclerosis and Diabetes Specialist's Perspective

Skip to main content

Latest Videos |view all videos

Showing 61 - 72 of 162 results

Previous| 1... 4 | 5 | 6 | 7 | 8 ...14 |Next

How do you see the benefit/safety risk equation shaping up for PCSK9 inhibitors based on the FOURIER and, most recently, the ODYSSEY Outcomes Trial?

How do you see the benefit/safety risk equation shaping up for PCSK9 inhibitors based on the FOURIER and, most recently, the ODYSSEY Outcomes Trial?

Does the presence of a stent in the setting of ACS color your approach to the degree of LDL-C reduction you would pursue?

Does the presence of a stent in the setting of ACS color your approach to the degree of LDL-C reduction you would pursue?

In the setting of secondary prevention for patients with diabetes, the role of LDL-C has special significance. How do you view the importance for the of PCSK9 inhibitors, therefore, specifically for reducing residual CV risk in the T2D population?

In the setting of secondary prevention for patients with diabetes, the role of LDL-C has special significance. How do you view the importance for the of PCSK9 inhibitors, therefore, specifically for reducing residual CV risk in the T2D population?

When is 70 mg/dL not good enough? Is this a threshold? What clinical factors suggest lower targets are better? What is happening at the vascular biology level?

When is 70 mg/dL not good enough? Is this a threshold? What clinical factors suggest lower targets are better? What is happening at the vascular biology level?

Can you describe the actual clinical phenotypes—actual patients referred to you by interventional or medical cardiologists—in which PCSK9 inhibition would represent a foundational approach to reduction of residual CV risk burden?

Can you describe the actual clinical phenotypes—actual patients referred to you by interventional or medical cardiologists—in which PCSK9 inhibition would represent a foundational approach to reduction of residual CV risk burden?

What is your experience deploying PCSK9 inhibitors in the clinic, and what are the most reliable and actionable triggers for deploying this program for CV risk reduction? And predictably achieving reimbursement and payor support for this therapy?

What is your experience deploying PCSK9 inhibitors in the clinic, and what are the most reliable and actionable triggers for deploying this program for CV risk reduction? And predictably achieving reimbursement and payor support for this therapy?

How do you interpret the reduction in associated overall mortality seen with alirocumab in the ODYSSEY Outcome Trial as compared to the lack of such findings—at least prior to results for the extension phase in FOURIER —for the evolocumab trial?

How do you interpret the reduction in associated overall mortality seen with alirocumab in the ODYSSEY Outcome Trial as compared to the lack of such findings—at least prior to results for the extension phase in FOURIER —for the evolocumab trial?

From a lipid medicine and preventive cardiovascular perspective, how do you triage the diabetic patient with ACS into a PCSK9-based treatment strategy for LDL-C reduction?

From a lipid medicine and preventive cardiovascular perspective, how do you triage the diabetic patient with ACS into a PCSK9-based treatment strategy for LDL-C reduction?

From the perspective of a lipid specialist, especially in light of the associated all-cause mortality reductions reported in ODYSSEY Outcomes, how should the clinician be thinking about PCSK9 inhibitors as a tool in their day-to-day practice?

From the perspective of a lipid specialist, especially in light of the associated all-cause mortality reductions reported in ODYSSEY Outcomes, how should the clinician be thinking about PCSK9 inhibitors as a tool in their day-to-day practice?

From a patient-centric, clinical profile perspective, which “high risk burden” patient populations do you, as an atherosclerosis specialist, single out for PCSK9-mediated LDL-C reduction?

Do you see safety signals associated with ultra-aggressive LDL-C lowering and what is the role of PAD as a risk factor guiding LDL-C reduction?

Do you see safety signals associated with ultra-aggressive LDL-C lowering and what is the role of PAD as a risk factor guiding LDL-C reduction?

Are you finding it easier to get authorization for reimbursement and approval of PCSK9 inhibitors now that prices have come down and we have seen clear outcome benefits in both major trials?

Are you finding it easier to get authorization for reimbursement and approval of PCSK9 inhibitors now that prices have come down and we have seen clear outcome benefits in both major trials?

Showing 61 - 72 of 162 results

Previous| 1... 4 | 5 | 6 | 7 | 8 ...14 |Next